In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAMES: Azzalure (Galderma); Bocouture (Merz); Botox (Allergan); Dysport (Ipsen); Myobloc (Solstice); Neurobloc (Eisai); Vistabel (Allergan); Xeomin (Merz)
- INDICATIONS: Blepharospasm, hemifacial spasm, spasmodic torticollis, sialorrhea, hyperhidrosis, strabismus, oromandibular dystonia, cervical dystonia, spasmodic dysphonia, chronic migraine; urinary incontinence in people with neurologic conditions such as spinal cord injury and multiple sclerosis who have overactivity of the bladder; cosmetic application for wrinkles
- SYNONYM: OnabotulinumtoxinA
- CLASS: Acetylcholine inhibitor, Neuromuscular blocker, Ophthalmic agent, toxin
- HALF-LIFE: 3–6 months
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aminoglycosides, Anticholinergics, Fesoterodine, Tiotropium, Trospium
Distant spread of toxin effect - postmarketing reports indicate that all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing diffculties. These symptoms have been reported hours to weeks after injection.
An antitoxin is available in the event of overdose or misinjection.
DISTANT SPREAD OF TOXIN EFFECT
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of onabotulinumtoxinA in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 01/22/2025
